Authors: Vanbilloen, HP Busson, R Verbruggen, AM

Citation: Hp. Vanbilloen et al., Structural requirements for stable binding of technetium-99m to derivatives of triglycine, J LABEL C R, 44(2), 2001, pp. 99-111

Authors: Vanbilloen, HP Cleynhens, BJ Verbruggen, AM

Citation: Hp. Vanbilloen et al., Synthesis and biological evaluation of the four isomers of technetium-99m labeled ethylenecysteamine cysteine (Tc-99m-ECC), the mono-acid derivative of Tc-99m-L,L-ethylenedicysteine, NUCL MED BI, 27(2), 2000, pp. 207-214

Authors: Vanbilloen, HP Mortelmans, L Verbruggen, AM

Citation: Hp. Vanbilloen et al., Reduction of contamination risks during clinical studies with Technegas - Reply, EUR J NUCL, 27(2), 2000, pp. 238-238

Authors: Dezutter, NA de Groot, TJ Vanbilloen, HP Janssen, GA Verbruggen, AM

Citation: Na. Dezutter et al., Preparation and biological evaluation of technetium-99m-L,L-propylenedicysteine, J LABEL C R, 42(6), 1999, pp. 553-565

Authors: Vanbilloen, HP Bauwens, J Mortelmans, L Verbruggen, AM

Citation: Hp. Vanbilloen et al., Reduction of contamination risks during clinical studies with Technegas, EUR J NUCL, 26(10), 1999, pp. 1349-1352